This is a trial that we are currently running in Italy. It’s 14 institutions running a multi-centred trial in which we are treating patients with ultra-hypofractionated radiotherapy on prostate cancer for intermediate and several prostate cancer disease and concomitant relugolix administration. And the relugolix is given in a short course ADT schedule, meaning that all patients were given six months of ADT...
This is a trial that we are currently running in Italy. It’s 14 institutions running a multi-centred trial in which we are treating patients with ultra-hypofractionated radiotherapy on prostate cancer for intermediate and several prostate cancer disease and concomitant relugolix administration. And the relugolix is given in a short course ADT schedule, meaning that all patients were given six months of ADT. And it will be very interesting to see if a higher rate of early testosterone recovery after the end of ADT will come with the same oncological benefits as standard concomitant ADT plus radiotherapy. We have currently enrolled 20 patients but we plan to end the enrollment by the end of 2027.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
